OBJECTIVE: This study examined the co-occurrence of anxiety/mood and personality disorders (PDs) in substance abusers, the impact of anxiety/ mood disorders on the symptom profiles of PDs, and the impact of anxiety/mood disorders and PDs on pre-treatment status. METHOD: Current anxiety/mood disorders and PDs and pre-treatment status were assessed using semi-structured interviews in 370 treated substance abusers. RESULTS: Anxiety/mood disorders and PDs frequently co-occurred, with the overall pattern of associations being non-specific. The strongest associations were of social phobia with avoidant and schizotypal PD, and of major depression with borderline PD. However, symptom profiles of PDs were not associated with anxiety/mood disorders. Finally, anxiety/mood disorders and PDs were both independently and differentially associated with poor pre-treatment characteristics. CONCLUSION: The findings suggest the clinical importance of obtaining both Axis I and Axis II diagnoses in treated substance abusers, and highlight the distinctiveness of the Axis I and Axis II disorders.
OBJECTIVE: This study examined the co-occurrence of anxiety/mood and personality disorders (PDs) in substance abusers, the impact of anxiety/ mood disorders on the symptom profiles of PDs, and the impact of anxiety/mood disorders and PDs on pre-treatment status. METHOD: Current anxiety/mood disorders and PDs and pre-treatment status were assessed using semi-structured interviews in 370 treated substance abusers. RESULTS:Anxiety/mood disorders and PDs frequently co-occurred, with the overall pattern of associations being non-specific. The strongest associations were of social phobia with avoidant and schizotypal PD, and of major depression with borderline PD. However, symptom profiles of PDs were not associated with anxiety/mood disorders. Finally, anxiety/mood disorders and PDs were both independently and differentially associated with poor pre-treatment characteristics. CONCLUSION: The findings suggest the clinical importance of obtaining both Axis I and Axis II diagnoses in treated substance abusers, and highlight the distinctiveness of the Axis I and Axis II disorders.
Authors: U W Preuss; M Johann; C Fehr; G Koller; N Wodarz; V Hesselbrock; W M Wong; M Soyka Journal: Eur Addict Res Date: 2009-07-20 Impact factor: 3.015
Authors: Attila J Pulay; Frederick S Stinson; Deborah A Dawson; Risë B Goldstein; S Patricia Chou; Boji Huang; Tulshi D Saha; Sharon M Smith; Roger P Pickering; W June Ruan; Deborah S Hasin; Bridget F Grant Journal: Prim Care Companion J Clin Psychiatry Date: 2009
Authors: Marc Walter; John G Gunderson; Mary C Zanarini; Charles A Sanislow; Carlos M Grilo; Thomas H McGlashan; Leslie C Morey; Shirley Yen; Robert L Stout; Andrew E Skodol Journal: Addiction Date: 2009-01 Impact factor: 6.526
Authors: Frederick S Stinson; Deborah A Dawson; Risë B Goldstein; S Patricia Chou; Boji Huang; Sharon M Smith; W June Ruan; Attila J Pulay; Tulshi D Saha; Roger P Pickering; Bridget F Grant Journal: J Clin Psychiatry Date: 2008-07 Impact factor: 4.384
Authors: Elisabeth M P Laurenssen; Maaike L Smits; Dawn L Bales; Dine J Feenstra; Hester V Eeren; Marc J Noom; Maartje A Köster; Zwaan Lucas; Reinier Timman; Jack J M Dekker; Patrick Luyten; Jan J V Busschbach; Roel Verheul Journal: BMC Psychiatry Date: 2014-11-18 Impact factor: 3.630
Authors: Elisabeth M P Laurenssen; Dieuwertje Westra; Martijn J Kikkert; Marc J Noom; Hester V Eeren; Anna J van Broekhuyzen; Jaap Peen; Patrick Luyten; Jan J V Busschbach; Jack J M Dekker Journal: BMC Psychiatry Date: 2014-05-22 Impact factor: 3.630